ESH AL 2018 | Breakthroughs in the treatment of elderly patients with AML

Farhad Ravandi

For a long while, the only treatment for acute myeloid leukemia (AML) was cytotoxic chemotherapy, which is often not well tolerated by elderly patients. Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, explains why he believes that combination therapies involving hypomethylating agents will be revolutionary in the treatment of the elderly patients with AML.

Share this video